Top 10 developments in lupus nephritis

Research output: Contribution to journalArticle

Abstract

Lupus nephritis affects up to 60 % of patients with systemic lupus erythematosus and is associated with worse clinical outcomes. Traditionally, it has been treated with high-dose immunosuppression consisting of cyclophosphamide and prednisone; however, recent trials have demonstrated mycophenolate mofetil as a safe and effective alternative for both induction and maintenance of disease. Other progress has been made in our understanding of the pathogenesis of lupus nephritis, outcomes in renal transplantation, and associations with genetic risk factors. This review highlights key developments in our understanding of lupus nephritis over the past decade.

Original languageEnglish (US)
Article number358
JournalCurrent Rheumatology Reports
Volume15
Issue number9
DOIs
StatePublished - Sep 2013

Fingerprint

Lupus Nephritis
Mycophenolic Acid
Prednisone
Systemic Lupus Erythematosus
Kidney Transplantation
Cyclophosphamide
Immunosuppression
Maintenance

Keywords

  • APOL1
  • Epidemiology
  • Induction therapy
  • Kidney
  • Lupus nephritis
  • Maintenance therapy
  • Membranous lupus nephritis
  • Multitargeted therapy
  • Mycophenolatemofetil
  • Proliferative lupus nephritis
  • Renal transplantation
  • Rituximab
  • SLE
  • Systemic lupus erythematosus
  • Treatment

ASJC Scopus subject areas

  • Rheumatology
  • Medicine(all)

Cite this

Top 10 developments in lupus nephritis. / Chen, Teresa; Fine, Derek M.

In: Current Rheumatology Reports, Vol. 15, No. 9, 358, 09.2013.

Research output: Contribution to journalArticle

@article{7c1c9ce0894d46dab3895d37edde0440,
title = "Top 10 developments in lupus nephritis",
abstract = "Lupus nephritis affects up to 60 {\%} of patients with systemic lupus erythematosus and is associated with worse clinical outcomes. Traditionally, it has been treated with high-dose immunosuppression consisting of cyclophosphamide and prednisone; however, recent trials have demonstrated mycophenolate mofetil as a safe and effective alternative for both induction and maintenance of disease. Other progress has been made in our understanding of the pathogenesis of lupus nephritis, outcomes in renal transplantation, and associations with genetic risk factors. This review highlights key developments in our understanding of lupus nephritis over the past decade.",
keywords = "APOL1, Epidemiology, Induction therapy, Kidney, Lupus nephritis, Maintenance therapy, Membranous lupus nephritis, Multitargeted therapy, Mycophenolatemofetil, Proliferative lupus nephritis, Renal transplantation, Rituximab, SLE, Systemic lupus erythematosus, Treatment",
author = "Teresa Chen and Fine, {Derek M}",
year = "2013",
month = "9",
doi = "10.1007/s11926-013-0358-7",
language = "English (US)",
volume = "15",
journal = "Current Rheumatology Reports",
issn = "1523-3774",
publisher = "Current Science, Inc.",
number = "9",

}

TY - JOUR

T1 - Top 10 developments in lupus nephritis

AU - Chen, Teresa

AU - Fine, Derek M

PY - 2013/9

Y1 - 2013/9

N2 - Lupus nephritis affects up to 60 % of patients with systemic lupus erythematosus and is associated with worse clinical outcomes. Traditionally, it has been treated with high-dose immunosuppression consisting of cyclophosphamide and prednisone; however, recent trials have demonstrated mycophenolate mofetil as a safe and effective alternative for both induction and maintenance of disease. Other progress has been made in our understanding of the pathogenesis of lupus nephritis, outcomes in renal transplantation, and associations with genetic risk factors. This review highlights key developments in our understanding of lupus nephritis over the past decade.

AB - Lupus nephritis affects up to 60 % of patients with systemic lupus erythematosus and is associated with worse clinical outcomes. Traditionally, it has been treated with high-dose immunosuppression consisting of cyclophosphamide and prednisone; however, recent trials have demonstrated mycophenolate mofetil as a safe and effective alternative for both induction and maintenance of disease. Other progress has been made in our understanding of the pathogenesis of lupus nephritis, outcomes in renal transplantation, and associations with genetic risk factors. This review highlights key developments in our understanding of lupus nephritis over the past decade.

KW - APOL1

KW - Epidemiology

KW - Induction therapy

KW - Kidney

KW - Lupus nephritis

KW - Maintenance therapy

KW - Membranous lupus nephritis

KW - Multitargeted therapy

KW - Mycophenolatemofetil

KW - Proliferative lupus nephritis

KW - Renal transplantation

KW - Rituximab

KW - SLE

KW - Systemic lupus erythematosus

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84880399953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880399953&partnerID=8YFLogxK

U2 - 10.1007/s11926-013-0358-7

DO - 10.1007/s11926-013-0358-7

M3 - Article

VL - 15

JO - Current Rheumatology Reports

JF - Current Rheumatology Reports

SN - 1523-3774

IS - 9

M1 - 358

ER -